Management of CKD with Hypertensive Urgency

Immediate Management Approach

The European Society of Cardiology recommends initiating or intensifying oral antihypertensive therapy with ACE inhibitors or ARBs as first-line agents, targeting BP reduction to <130/80 mmHg over hours to days, not minutes, in CKD patients with hypertensive urgency 1, 2, 3
The European Society of Cardiology suggests targeting systolic BP to 120-129 mmHg if tolerated in patients with eGFR >30 mL/min/1.73 m² 1
A systolic BP range of 130-139 mmHg is acceptable for diabetic or non-diabetic CKD patients, according to the European Society of Cardiology 1, 3

The Kidney International journal recommends titrating ACE inhibitors to the highest tolerated dose (up to 40 mg daily) as proven benefits were achieved at target doses in clinical trials 4, 5, 6
The European Society of Cardiology suggests using ARBs as alternative first-line therapy if ACE inhibitors cause cough or angioedema 2, 3

The Kidney International journal recommends checking serum creatinine and potassium within 2-4 weeks of initiation or dose increase of ACE inhibitors or ARBs 4, 5, 6, 7
The Kidney International journal suggests continuing ACE inhibitor/ARB unless creatinine rises >30% within 4 weeks 4, 5, 6, 7

The Praxis Medical Insights guideline recommends adding a long-acting dihydropyridine calcium channel blocker or thiazide-like diuretic as second-line agents for inadequate control 3
The Praxis Medical Insights guideline suggests using loop diuretics for eGFR <30 mL/min or creatinine >2.0 mg/dL, as thiazides become ineffective 3

The Kidney International journal recommends adding an SGLT2 inhibitor for patients with diabetes and CKD, if eGFR ≥20 mL/min/1.73 m² 4, 5, 6
The Kidney International journal suggests continuing SGLT2 inhibitors even if eGFR falls below 20 mL/min/1.73 m², unless not tolerated 4, 5, 6

The Kidney International journal recommends continuing ACE inhibitor/ARB even when eGFR falls below 30 mL/min/1.73 m² 4, 5, 6, 7
The Kidney International journal suggests only considering discontinuation at eGFR <15 mL/min/1.73 m² if symptomatic hypotension or uremic symptoms develop 4, 5, 6, 7

The Kidney International journal recommends avoiding the combination of ACE inhibitor + ARB + direct renin inhibitor, as it increases adverse events without benefit 4, 5, 6, 7
The Kidney International journal suggests avoiding dual RASi therapy (ACE inhibitor + ARB) due to increased risk of hyperkalemia, hypotension, and acute kidney injury 4, 5, 6, 7